View
222
Download
0
Category
Preview:
Citation preview
8/7/2019 MYFORTIC NOVARTIS
1/13
MICOFENOLICO CIDO
MICOFENOLATO SDICOCON CUBIERTA ENTERICA
NIDIA A- CALLE REYMERMDICO NEFRLOGA
HNLNSPNP
MYFORTIC
8/7/2019 MYFORTIC NOVARTIS
2/13
DROGAS INMUNOSUPRESORAS: LUGARES DE ACCION ENEL MODELO DE TRES SEALES
n engl j med 351;26 december 23, 2004
8/7/2019 MYFORTIC NOVARTIS
3/13
y AGENTES DIRIGIDOS FRENTE A LA SEAL UNO
Anticuerpo monoclonal OKT3 se une a una de lassubunidades de 20 kd del complejo CD3 determinando laendocitosis del receptor de las clulas T.
Anticuerpos policlonales (globulina antitimoctica) se dirigefrente a la molcula CD3 y a una serie de marcadores celulares desuperficie.
Inhibidores de la calcineurina: Ciclosporina y el Tacrolimus:
inhiben la actividad fosfatasa de la calcineurina cuando se unen a alas protenas fijadoras de inmunofilina en el citoplasmaproduciendo una inhibicin de la transcripcin del gen de la IL2.
8/7/2019 MYFORTIC NOVARTIS
4/13
8/7/2019 MYFORTIC NOVARTIS
5/13
y LOSLINFOCITOS REQUIERENNIVELESADECUADOS DELOS
NUCLETIDOS PURNICOS:GUANOSINA YDEOXIGUANOSINA Y NIVELESREDUCIDOS DE ADENOSINA YDEOXIADENOSINA PARAPROLIFERAR.
y ESTOSNUCLETIDOSSE
SINTETIZAN ENLASCLULASHUMANASA TRAVS DE DOSVAS:LA VA DE NOVO Y LA VAALTERNAO DE RESCATE. LOSLINFOCITOS UTILIZANFUNDAMENTALMENTE LA VADE NOVO, LO QUE LES HACESENSIBLESA LA ACCIN DE
MPA QUE LLEVAR A LADISMINUCIN DE LA SNTESISDE GTP, COMPOMENTEFUNDAMENTALDE LATRASNFORMACIN MITGENADELLINFOCITO
Nefrologa. Vol. 25. Nm. 3.2005
8/7/2019 MYFORTIC NOVARTIS
6/13
ACIDO MICOFENOLICOy Se aisl por primera vez en 1898 a partir del moho Penicillin
glaucum, estudiado inicialmente como antibitico.
y Es un inhibidor reversible de la IMPDH.
y
Derivados del ACIDO MICOFENOLICO:MICOFENOLATO MOFETIL
MICOFENOLATO SDICO CON CUBIERTAENTRICA.
8/7/2019 MYFORTIC NOVARTIS
7/13
Exposicin de MPA en el post-trasplante
Hale MD et al. Clin PharmacolTher 1998; 64: 672-683.
4g MMF
2 g MMF
1g MMF
8/7/2019 MYFORTIC NOVARTIS
8/13
j Alta variacion entre pacientes
j La exposicin se corelaciona inversamente con el
rechazo.
j La exposicin va en aumento en el postrasplante.
MPA monitoreo puede ser util por :
v. Gelder T et al. Transplantation 68: 261-266, 1999Hale M et al. Clin Pharmacol Ther 64: 672-683, 1998
Pero...La monitorizacin mejoraria los resultados???
8/7/2019 MYFORTIC NOVARTIS
9/13
8/7/2019 MYFORTIC NOVARTIS
10/13
8/7/2019 MYFORTIC NOVARTIS
11/13
y 1: INDUCTION THERAPY1.1: We recommend starting a combination of immunosuppressivemedications before, or at the time of, kidney transplantation. (1A)1.2: We recommend including induction therapy with a biologic
agent as part of the initial immunosuppressive regimen in KTRs.(1A)1.2.1: We recommend that an IL2-RA be the first-lineinduction therapy. (1B)1.2.2: We suggest using a lymphocyte-depleting agent,
rather than an IL2-RA, for KTRs at high immunologic risk.(2B)
IL2-RA, interleukin 2 receptor antagonist; KTRs, kidney transplantrecipients.
8/7/2019 MYFORTIC NOVARTIS
12/13
y 2: INITIAL MAINTENANCEIMMUNOSUPPRESSIVE MEDICATIONS2.1: We recommend using a combination of immunosuppressive medications asmaintenance therapy including a
CNI and an antiproliferative agent, with or without corticosteroids. (1B)2.2: We suggest that tacrolimus be the first-line CNI used. (2A)
2.2.1: We suggest that tacrolimus or CsA be started before or at the timeof transplantation, rather than delayed until the onset of graft function. (2D
tacrolimus; 2B CsA)2.3: We suggest that mycophenolate be the first-line antiproliferative agent.(2B)2.4: We suggest that, in patients who are at low immunological risk and whoreceive induction therapy, corticosteroids could be discontinued during the firstweek after transplantation. (2B)
2.5: We recommend that if mTORi are used, they should not be started untilgraft function is established and surgical wounds are healed. (1B)CNI, calcineurin inhibitor; CsA, cyclosporine A; mTORi, mammalian target of
rapamycin inhibitor(s).
8/7/2019 MYFORTIC NOVARTIS
13/13
y 3: LONG-TERM MAINTENANCE IMMUNOSUPPRESSIVE
MEDICATIONS3.1: We suggest using the lowest planned doses ofmaintenance immunosuppressive medications by 24 months aftertransplantation, if there has been no acute rejection. (2C)
3.2: We suggest that CNIs be continued rather than
withdrawn. (2B)3.3: If prednisone is being used beyond the first week after
transplantation, we suggest prednisone be continued rather thanwithdrawn. (2C)
CNI, calcineurin inhibitor.
Recommended